- Home
- CMMB vs BHIL Comparison
CMMB vs BHIL Comparison
Compare CMMB & BHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- BHIL
- Stock Information
- Founded
- CMMB 2004
- BHIL 2012
- Country
- CMMB Israel
- BHIL United States
- Employees
- CMMB N/A
- BHIL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- BHIL Packaged Foods
- Sector
- CMMB Health Care
- BHIL Consumer Staples
- Exchange
- CMMB Nasdaq
- BHIL Nasdaq
- Market Cap
- CMMB 27.0M
- BHIL 27.1M
- IPO Year
- CMMB N/A
- BHIL N/A
- Fundamental
- Price
- CMMB $1.60
- BHIL $4.08
- Analyst Decision
- CMMB Strong Buy
- BHIL
- Analyst Count
- CMMB 3
- BHIL 0
- Target Price
- CMMB $7.33
- BHIL N/A
- AVG Volume (30 Days)
- CMMB 119.1K
- BHIL 13.6K
- Earning Date
- CMMB 11-14-2024
- BHIL 11-12-2024
- Dividend Yield
- CMMB N/A
- BHIL N/A
- EPS Growth
- CMMB N/A
- BHIL N/A
- EPS
- CMMB N/A
- BHIL N/A
- Revenue
- CMMB N/A
- BHIL $466,725,000.00
- Revenue This Year
- CMMB N/A
- BHIL N/A
- Revenue Next Year
- CMMB N/A
- BHIL N/A
- P/E Ratio
- CMMB N/A
- BHIL N/A
- Revenue Growth
- CMMB N/A
- BHIL 139.60
- 52 Week Low
- CMMB $0.42
- BHIL $4.11
- 52 Week High
- CMMB $2.55
- BHIL $11.03
- Technical
- Relative Strength Index (RSI)
- CMMB 52.53
- BHIL 13.19
- Support Level
- CMMB $1.54
- BHIL $5.26
- Resistance Level
- CMMB $1.73
- BHIL $7.45
- Average True Range (ATR)
- CMMB 0.16
- BHIL 0.41
- MACD
- CMMB 0.01
- BHIL -0.28
- Stochastic Oscillator
- CMMB 45.45
- BHIL 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About BHIL Benson Hill Inc.
Benson Hill Inc is an ag-tech company specializing in soy protein innovation. The company has one business segment Ingredient. The company focuses on seed innovation through proprietary germplasm and the CropOS platform. This platform integrates protein, genomic, and strategic data for predictive breeding using AI and ML. They operate a Crop Accelerator for rapid prototyping. Benson Hill is developing a seed portfolio for protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company's revenue can be disaggregated into product categories: Proprietary and Non-Proprietary. Proprietary revenue is defined as any sale of a proprietary bean. Non-Proprietary revenue is all other revenue from non-Proprietary sources.